Siga Technologies receives FDA approval for TPOXX to treat smallpox
The U.S. Food and Drug Administration approved TPOXX, which it called "the first drug with an indication for treatment of smallpox." FDA Commissioner Scott Gottlieb said: "To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today's approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon. This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today's action reflects the FDA's commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products." The FDA granted approval of TPOXX to Siga Technologies.